RxDoctor Payments Data

Fanny Berg

Wilmington, DENPI 1720182256

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.2% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,965 and has fallen 92.1% since, to $155 in 2022.

$2,592in general payments, 2019–2025

Across 125 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$511
  • Novartis$229
  • Pfizer$211
  • Lilly USA, LLC$209
  • Amgen$179
  • UCB, Inc.$167
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$2,52097%
  • Education$723%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →